ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses ...

LAUSANNE, Switzerland, June 09, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in

Related Keywords

Switzerland ,United States ,London ,City Of ,United Kingdom ,New Jersey ,Lugano ,Ticino ,Kathryna Logronio ,Paolof Caimi ,Mehdi Hamadani ,Parco Ciani ,Lausanne Biop ,Eugenia Litz ,Mary Ann Ondish ,Loncastuximab Tesirine ,John Wiley ,Mohamed Zaki ,European Hematology Association ,College Of Wisconsin ,Sons Inc ,Company Annual Report On Form ,European Medicines Agency ,Linkedin ,International Conference On Malignant Lymphoma ,Overland Pharmaceuticals ,Biosciences Inc ,European Commission ,Exchange Commission ,Cleveland Clinic Taussig Cancer Center ,European Union ,Wiley Online Library On ,Mitsubishi Tanabe Pharma Corporation ,Drug Administration ,Company On Twitter ,International Conference ,Malignant Lymphoma ,Chief Medical Officer ,Medical College ,Term Responses ,Updated Results From ,Pivotal Phase ,Refractory Diffuse Largeb Cell Lymphoma ,B Cell And Double Hit ,Preclinical Model ,Lugano Poster ,Marquee Parco ,Ongoing Phase ,Open Label Study ,Refractoryb Cell Non Hodgkin Lymphoma ,Abstract Book ,Wiley Online Library ,San Francisco Bay Area ,Private Securities Litigation Reform Act ,Swedish Orphan Biovitrum ,European Economic Area ,Infrastructure Investment ,Jobs Act ,Healthcare Royalty Management ,Blue Owl ,Annual Report , ,